Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;40(10):638-658.
doi: 10.1089/jop.2024.0103. Epub 2024 Oct 2.

Inflammation in Dry Eye Disease-Pathogenesis, Preclinical Animal Models, and Treatments

Affiliations
Review

Inflammation in Dry Eye Disease-Pathogenesis, Preclinical Animal Models, and Treatments

Santosh Bhujbal et al. J Ocul Pharmacol Ther. 2024 Dec.

Abstract

Dry eye disease (DED) is a rapidly growing ocular surface disease with a significant socioeconomic impact that affects the patients' visual function and, thus, their quality of life. It is distinguished by a loss of tear film homeostasis, leading to tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities, with all of these playing etiological roles in the propagation of the vicious DED circle. While current treatments primarily focus on reducing tear film instability and hyperosmolarity, increasingly more attention is being placed on tackling the underlying inflammation that propagates and potentiates these factors. As such, preclinical models are crucial to further elucidate the DED pathophysiology and develop novel therapeutic strategies. This review outlines the role of inflammation in DED, highlighting related signs and diagnostic tools before focusing on relevant preclinical animal models and potential therapeutic strategies to tackle DED-associated inflammation.

Keywords: anti-inflammatory therapy; dry eye disease; inflammation; ocular surface; preclinical models.

PubMed Disclaimer

LinkOut - more resources